Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy | Zendy

Loke Justin | Zendy; Metzner Marlen | Zendy; Boucher Rebecca | Zendy; Jackson Aimee | Zendy; Hopkins Louise | Zendy; Pavlu Jiri | Zendy; Tholouli Eleni | Zendy; Drummond Mark | Zendy; Peniket Andy | Zendy; Bishop Rebecca | Zendy; Fox Sonia | Zendy; Vyas Paresh | Zendy; Craddock Charles | Zendy

Premium

Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy

Author(s) -

Loke Justin,

Metzner Marlen,

Boucher Rebecca,

Jackson Aimee,

Hopkins Louise,

Pavlu Jiri,

Tholouli Eleni,

Drummond Mark,

Peniket Andy,

Bishop Rebecca,

Fox Sonia,

Vyas Paresh,

Craddock Charles

Publication year - 2022

Publication title -

british journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.907

H-Index - 186

eISSN - 1365-2141

pISSN - 0007-1048

DOI - 10.1111/bjh.17823

Subject(s) - azacitidine , medicine , romidepsin , myeloid leukaemia , chemotherapy , oncology , decitabine , myeloid leukemia , histone deacetylase , histone , gene expression , chemistry , dna methylation , gene , biochemistry

Summary Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro . The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m 2 on Days 8 and 15, with AZA 75 mg/m 2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next‐generation sequencing studies demonstrated important insights into therapy resistance.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research